Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

9.16USD
18 Dec 2018
Change (% chg)

-- (--)
Prev Close
$9.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
223,511
52-wk High
$21.69
52-wk Low
$8.94

Latest Key Developments (Source: Significant Developments)

Karyopharm Q3 Loss Per Share $0.79
Thursday, 8 Nov 2018 07:00am EST 

Nov 8 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q3 LOSS PER SHARE $0.79.Q3 EARNINGS PER SHARE VIEW $-0.89 -- THOMSON REUTERS I/B/E/S.KARYOPHARM THERAPEUTICS - U.S. FDA ACCEPTS CO'S NEW DRUG APPLICATION FOR SELINEXOR AND GRANTS PRIORITY REVIEW; PDUFA ACTION DATE OF APRIL 6, 2019.FAST TRACK DESIGNATION RECEIVED FOR SELINEXOR IN RELAPSED OR REFRACTORY DLBCL.COMPLETED $172.5 MILLION CONVERTIBLE SENIOR NOTE OFFERING; CASH-ON-HAND EXPECTED TO FUND CO INTO 2Q 2020.KARYOPHARM THERAPEUTICS - TO SUBMIT MARKETING AUTHORIZATION APPLICATION TO EMA IN EARLY 2019 WITH A REQUEST FOR CONDITIONAL APPROVAL FOR SELINEXOR.  Full Article

Karyopharm Therapeutics Announces Management Change
Friday, 26 Oct 2018 07:00am EDT 

Oct 26 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS ANNOUNCES MANAGEMENT CHANGE.KARYOPHARM THERAPEUTICS - MIKE FALVEY, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER, INTENDS TO LEAVE CO TO PURSUE OTHER INTERESTS.KARYOPHARM THERAPEUTICS INC - EXECUTIVE SEARCH WILL COMMENCE IMMEDIATELY TO FILL FALVEY'S POSITION.KARYOPHARM THERAPEUTICS - FALVEY TO CONTINUE CURRENT RESPONSIBILITIES UNTIL SUCCESSOR NAMED TO ENSURE "NO DISRUPTION IN FINANCIAL LEADERSHIP OF CO".  Full Article

Karyopharm's Selinexor Achieves 26.2 Pct Overall Response Rate In Phase 2b Storm Study
Thursday, 13 Sep 2018 07:20pm EDT 

Sept 13 (Reuters) - Karyopharm Therapeutics Inc ::PHASE 2B STORM DATA EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA PRESENTED AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY 2018 ANNUAL MEETING.KARYOPHARM THERAPEUTICS-ORAL SELINEXOR ACHIEVES 26.2% OVERALL RESPONSE RATE AND DURATION OF RESPONSE OF 4.4 MONTHS IN OVERALL STUDY POPULATION.COMMERCIAL PREPARATION UNDERWAY; NEW DRUG APPLICATION SUBMITTED TO FDA.  Full Article

Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma
Monday, 30 Apr 2018 04:05pm EDT 

April 30 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - SELINEXOR CONTINUES TO DEMONSTRATE A PREDICTABLE AND MANAGEABLE TOLERABILITY PROFILE.KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2018.KARYOPHARM THERAPEUTICS INC - REGARDING STORM STUDY'S PRIMARY OBJECTIVE, ORAL SELINEXOR ACHIEVED A 25.4% OVERALL RESPONSE RATE.KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019.KARYOPHARM THERAPEUTICS INC - EXPECTING TO COMPLETE ENROLLMENT IN BOSTON STUDY BY END OF 2018, WITH TOP-LINE DATA ANTICIPATED IN 2019.  Full Article

Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80
Thursday, 15 Mar 2018 07:00am EDT 

March 15 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS.Q4 LOSS PER SHARE $0.80.Q4 EARNINGS PER SHARE VIEW $-0.65 -- THOMSON REUTERS I/B/E/S.PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MYELOMA REMAINS ON TRACK.TOP-LINE DATA FROM PHASE 2B STORM STUDY EXPECTED END OF APRIL 2018.KARYOPHARM - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, INCLUDING RESTRICTED CASH, TOTALED $176.4 MILLION, VERSUS $175.5 MILLION AT DEC 31, 2016.EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q1 2019.QTRLY LICENSE AND OTHER REVENUE $1.5 MILLION VERSUS $ 47,000.  Full Article

Karyopharm Announces Agreement For Biogen To Acquire KPT-350
Thursday, 25 Jan 2018 06:30am EST 

Jan 25 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS.KARYOPHARM THERAPEUTICS INC - DEAL VALUED AT UP TO $217 MILLION.KARYOPHARM THERAPEUTICS - ‍BIOGEN IS ACQUIRING KPT-350 AND OTHER ASSETS TARGETING CERTAIN NEUROLOGICAL CONDITIONS, INCLUDING ALS.KARYOPHARM - DEAL INCLUDES $10 MILLION UPFRONT PAYMENT TO KARYOPHARM, AND POTENTIAL $207 MILLION IN FUTURE MILESTONES, PLUS ROYALTIES.KARYOPHARM - CO ALSO ELIGIBLE TO GET TIERED ROYALTIES FROM BIOGEN THAT REACH LOW DOUBLE DIGITS BASED ON FUTURE NET SALES OF SOME PRODUCT CANDIDATES.  Full Article

Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock
Friday, 1 Dec 2017 04:26pm EST 

Dec 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION.KARYOPHARM THERAPEUTICS - ON DEC 1, CO ENTERED INTO AMENDMENT NO. 2 TO CONTROLLED EQUITY OFFERING SALES AGREEMENT, DATED DECEMBER 7, 2015 - SEC FILING.  Full Article

Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​
Monday, 6 Nov 2017 04:32pm EST 

Nov 6 (Reuters) - Karyopharm Therapeutics Inc :Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​.  Full Article

Karyopharm Q3 loss per share $0.65
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports third quarter 2017 financial results and highlights recent progress.Q3 loss per share $0.65.Q3 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.Karyopharm Therapeutics Inc - ‍expect to report top-line results of phase 2b storm study by april 2018​.  Full Article

Karyopharm reports positive data from ongoing cancer drug study
Wednesday, 20 Sep 2017 07:00am EDT 

Sept 20 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma.Karyopharm Therapeutics - ‍phase 3 portion of 2/3 seal​ study commenced; expanded to include North America, Europe, expected to enroll up to 222 patients.Karyopharm Therapeutics Inc - ‍top-line of data expected by end of 2019 for 2/3 seal study​.Karyopharm Therapeutics - ‍FDA has confirmed its acceptance of proposed phase 3 seal study design, including PFS primary endpoint.  Full Article